LivaNova PLC (LIVN)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $5.03B
Last updated: Nov 17, 2026 at 11:06 AM ET
LivaNova PLC (LIVN) Financials: Revenue, Profit and Cash Flow
LivaNova reported revenue of $1.39B for the fiscal year ended Dec 31, 2025, up 10.7% from the year before. That year, net income was -$242.50M with a net margin of -17.5%, operating cash flow was $254.30M and free cash flow was $173.20M. The quarter ended Sep 30, 2026 had revenue of $393.10M and net income of $34.30M.
Revenue and Margins
The operating margin was 14.4% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $1.21B, a compound annual rate of 1.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1.39B | +10.7% | 67.7% | 14.4% | -17.5% |
| Dec 2024 | $1.25B | +8.7% | 69.5% | 10.3% | 5.0% |
| Dec 2023 | $1.15B | +12.9% | 66.9% | -5.9% | 1.5% |
| Dec 2022 | $1.02B | -1.3% | 69.2% | -7.5% | -8.4% |
| Dec 2021 | $1.04B | +10.8% | 68.2% | -0.1% | -13.1% |
| Dec 2020 | $934.24M | -13.8% | 63.7% | -29.3% | -37.3% |
| Dec 2019 | $1.08B | -2.1% | 66.8% | -15.8% | -14.5% |
| Dec 2018 | $1.11B | +9.4% | 66.4% | -22.4% | -17.1% |
| Dec 2017 | $1.01B | -16.6% | 64.4% | 9.5% | -2.5% |
| Dec 2016 | $1.21B | N/A | 58.0% | -2.3% | -5.2% |
Income Statement
In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, net income rose 28.0% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.39B | $1.25B | $1.15B | $1.02B | $1.04B | $934.24M | $1.08B | $1.11B | $1.01B | $1.21B |
| Cost of revenue | $448.20M | $382.56M | $382.30M | $314.58M | $329.37M | $339.48M | $360.37M | $372.50M | $360.70M | $509.50M |
| Gross profit | $939.90M | $870.87M | $771.25M | $707.23M | $705.99M | $594.76M | $723.80M | $734.50M | $651.60M | $704.40M |
| Research and development | $185.80M | $182.51M | $193.82M | $155.81M | $183.41M | $152.90M | $197.15M | $146.00M | $109.70M | $122.50M |
| Operating income | $199.40M | $129.05M | -$68.50M | -$76.75M | -$784.00K | -$273.90M | -$171.55M | -$248.10M | $95.70M | -$27.60M |
| Net income | -$242.50M | $63.23M | $17.55M | -$86.25M | -$135.82M | -$348.82M | -$157.64M | -$189.40M | -$25.10M | -$62.80M |
| EBITDA | N/A | $202.52M | $38.48M | $30.90M | N/A | $20.33M | $131.48M | -$167.68M | $199.13M | $121.19M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $393.10M | $390.60M | $362.26M | $360.86M | $357.80M | $352.52M | $316.86M | $321.83M | $318.12M | $318.57M | $294.91M | $310.13M |
| Gross profit | $265.00M | $273.70M | $244.85M | $239.78M | $244.90M | $238.99M | $220.78M | $219.35M | $225.26M | $214.88M | $207.39M | $190.17M |
| Operating income | $28.40M | $49.50M | $52.19M | $42.62M | $54.00M | $54.18M | $48.62M | $37.02M | $35.62M | $40.17M | $16.25M | -$87.99M |
| Net income | $34.30M | $108.60M | $22.30M | $30.88M | $26.80M | $27.16M | -$327.32M | $55.89M | $32.95M | $16.33M | -$41.94M | $16.34M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $376.69M by $258.92M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.61B | $2.51B | $2.43B | $2.29B | $2.20B | $2.40B | $2.41B | $2.55B | $2.50B | $2.34B |
| Current assets | $1.10B | $1.13B | $988.16M | $886.14M | $679.18M | $708.04M | $549.44M | $533.30M | $869.90M | $620.10M |
| Cash and equivalents | $635.60M | $428.86M | $266.50M | $214.17M | $207.99M | $252.83M | $61.14M | $47.20M | $93.60M | $39.80M |
| Total liabilities | $1.41B | $1.19B | $1.15B | $1.09B | $906.31M | $1.29B | $1.03B | $1.05B | $688.60M | $635.70M |
| Short-term debt | $31.50M | $87.04M | $26.47M | $32.81M | $240.93M | $24.62M | $88.51M | $28.80M | $84.03M | $47.70M |
| Long-term debt | $345.19M | $549.62M | $568.54M | $518.07M | $9.80M | $642.30M | $260.33M | $139.54M | $61.96M | $75.22M |
| Shareholder equity | $1.20B | $1.32B | $1.28B | $1.21B | $1.29B | $1.11B | $1.38B | $1.50B | $1.82B | $1.71B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.71B | $2.64B | $2.52B | $2.61B | $2.56B | $2.51B | $2.56B | $2.51B | $2.52B | $2.45B | $2.46B | $2.43B |
| Total liabilities | $1.34B | $1.32B | $1.30B | $1.41B | $1.40B | $1.38B | $1.52B | $1.19B | $1.21B | $1.21B | $1.24B | $1.15B |
| Cash and equivalents | $563.50M | $516.62M | $539.70M | $635.60M | $646.08M | $593.64M | $738.44M | $428.86M | $346.37M | $329.24M | $309.19M | $266.50M |
| Shareholder equity | $1.37B | $1.33B | $1.21B | $1.20B | $1.16B | $1.12B | $1.03B | $1.32B | $1.31B | $1.24B | $1.22B | $1.28B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 68.1% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $254.30M | $183.04M | $74.91M | $69.90M | $102.54M | -$79.40M | -$91.14M | $120.50M | $91.30M | $90.20M |
| Capital expenditures | $81.10M | $47.11M | $34.98M | $26.50M | $25.48M | $35.00M | $24.69M | $38.00M | $34.10M | $37.20M |
| Free cash flow | $173.20M | $135.93M | $39.93M | $43.40M | $77.07M | -$114.40M | -$115.83M | $82.50M | $57.20M | $53.00M |
| Dividends paid | N/A | N/A | N/A | N/A | N/A | N/A | $4.84M | N/A | $0 | $0 |
| Investing cash flow | -$72.90M | -$48.16M | -$40.33M | -$38.40M | $36.90M | -$41.80M | -$41.29M | -$120.60M | -$52.90M | -$38.20M |
| Financing cash flow | -$285.70M | $18.55M | $21.48M | $280.10M | -$181.48M | $310.80M | $146.58M | -$42.30M | $11.30M | -$124.30M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $73.60M | $66.59M | $15.22M | $82.40M | $85.06M | $62.92M | $23.97M | $78.71M | $50.99M | $43.36M | $9.98M | $53.96M |
| Capital expenditures | $30.80M | $31.55M | $14.29M | $32.20M | $22.88M | $15.15M | $10.79M | $10.41M | $18.15M | $12.16M | $6.40M | $12.92M |
| Free cash flow | $42.80M | $35.04M | $926.00K | $50.20M | $62.18M | $47.77M | $13.18M | $68.30M | $32.85M | $31.20M | $3.58M | $41.04M |
Frequently Asked Questions About LIVN
What is LivaNova's annual revenue?
LivaNova reported revenue of $1.39B for the fiscal year ended Dec 31, 2025.
How fast is LivaNova's revenue growing?
Revenue was up 10.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 10.8%.
Is LivaNova profitable?
No. LivaNova reported net income of -$242.50M for the fiscal year ended Dec 31, 2025, with a net margin of -17.5%.
How much free cash flow does LIVN generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $254.30M minus capital expenditures of $81.10M produced free cash flow of $173.20M.
How much debt does LivaNova have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $345.19M, short-term debt of $31.50M and cash and equivalents of $635.60M.
LIVN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts